- Home
- CITE vs CTMX Comparison
CITE vs CTMX Comparison
Compare CITE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CITE
- CTMX
- Stock Information
- Founded
- CITE 2021
- CTMX 2008
- Country
- CITE United States
- CTMX United States
- Employees
- CITE N/A
- CTMX N/A
- Industry
- CITE
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- CITE
- CTMX Health Care
- Exchange
- CITE NYSE
- CTMX Nasdaq
- Market Cap
- CITE 91.0M
- CTMX 100.5M
- IPO Year
- CITE 2022
- CTMX 2015
- Fundamental
- Price
- CITE $11.47
- CTMX $1.20
- Analyst Decision
- CITE
- CTMX Buy
- Analyst Count
- CITE 0
- CTMX 6
- Target Price
- CITE N/A
- CTMX $5.77
- AVG Volume (30 Days)
- CITE 58.0
- CTMX 606.6K
- Earning Date
- CITE 01-01-0001
- CTMX 11-05-2024
- Dividend Yield
- CITE N/A
- CTMX N/A
- EPS Growth
- CITE N/A
- CTMX N/A
- EPS
- CITE N/A
- CTMX 0.13
- Revenue
- CITE N/A
- CTMX $119,569,000.00
- Revenue This Year
- CITE N/A
- CTMX N/A
- Revenue Next Year
- CITE N/A
- CTMX N/A
- P/E Ratio
- CITE N/A
- CTMX $8.91
- Revenue Growth
- CITE N/A
- CTMX 50.41
- 52 Week Low
- CITE $10.73
- CTMX $1.04
- 52 Week High
- CITE $12.25
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- CITE 84.10
- CTMX 47.05
- Support Level
- CITE $11.29
- CTMX $1.09
- Resistance Level
- CITE $11.49
- CTMX $1.27
- Average True Range (ATR)
- CITE 0.00
- CTMX 0.07
- MACD
- CITE 0.01
- CTMX 0.01
- Stochastic Oscillator
- CITE 84.62
- CTMX 61.11
About CITE CARTICA ACQUISITION CORP
Cartica Acquisition Corp is a blank check company.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.